Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs
08:47am, Friday, 18'th Apr 2025
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
Johnson & Johnson Pivots Its AI Strategy
07:00am, Friday, 18'th Apr 2025
The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or underdelivering.
3 High-Yield Dividend All-Stars to Buy Right Now
11:19am, Thursday, 17'th Apr 2025
The good news for investors seeking high-yield dividend stocks to buy right now is that there are a number of top options for investors to consider in the high-yield dividend world.
Here's How You Should Play JNJ Stock After Q1 Earnings Beat
09:05am, Thursday, 17'th Apr 2025
Those who own JNJ stock may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges.
Why Most Dividend Retirement Strategies Fail: How To Retire With Dividends
08:05am, Thursday, 17'th Apr 2025
Most high-yield strategies are ticking time bombs. Don't get wiped out when the next downturn hits. Discover the only portfolio blend that can deliver sustainable and rising dividends through inflatio
The Relief Rally Is Over: 4 Incredible Dividend Monarchs Are Our Safest Ideas Now
07:42am, Thursday, 17'th Apr 2025
While it was fun while it lasted, as we have discussed before, inevitably, after vicious sell-offs like the one we saw from the market peak in February, which pushed the S&P 500 and the Nasdaq quickly
4 Reasons Johnson & Johnson Could Be the Perfect Stock to Own in Today's Turbulent Market
04:51am, Thursday, 17'th Apr 2025
It's less than four months into the year, and many investors are already exhausted. The wild stock market swings fueled by the Trump administration's tariffs are to blame.
This Super-Safe High-Yield Stock Just Extended Its Dividend Growth Streak to 63 Years in a Row
04:07am, Thursday, 17'th Apr 2025
Johnson & Johnson (JNJ 0.22%) continues to treat its investors like royalty. The healthcare behemoth recently gave them another raise, increasing its dividend payment by 4.8%.
Buy These Defensive Stocks After Beating Earnings Expectations?: ACI, JNJ
07:35pm, Wednesday, 16'th Apr 2025
Johnson & Johnson (JNJ) and Albertsons Companies' (ACI) stock have provided a pleasant hedge against market volatility and were able to exceed their quarterly expectations on Wednesday.
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
04:28pm, Wednesday, 16'th Apr 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th. Management will participate in a
Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffs
12:51pm, Wednesday, 16'th Apr 2025
What Johnson & Johnson and Eli Lilly are saying about Trump's pharmaceutical tariffs, and Dexcom scores FDA approval for its glucose monitoring system.
ETFs in Focus Post JNJ's Q1 Earnings Beat, Dividend Hike
11:00am, Wednesday, 16'th Apr 2025
Johnson & Johnson reports strong first-quarter 2025 results, raises revenue guidance and boosts its quarterly dividends.
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?
07:58am, Wednesday, 16'th Apr 2025
On the one hand, the company beat on the top and bottom lines and offered better-than-expected guidance. On the other hand, JNJ acknowledged the likelihood of a $400 million tariff hit on the company'
Portfolio positioning amid tariff uncertainty, Johnson & Johnson's Q1 earnings beat, HPE stock jumps
08:05pm, Tuesday, 15'th Apr 2025
Josh speaks to experts about the state of markets amid President Trump's tariff pause and trade tensions escalating with China. Other topics include bank earnings, Johnson & Johnson reporting a Q1 ear
J&J's Spravato momentum points to commercial viability of psychedelics for mental health, analysts say
03:30pm, Tuesday, 15'th Apr 2025
Another quarter of consistent growth for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato bodes well for other psychedelics, analysts at Jefferies believe. They see consistent quarter-ov
